论文部分内容阅读
【目的】观察青蒿素哌喹片(Artequick)治疗间日疟的有效性、安全性及临床剂量。【方法】对62例间日疟患者采用成人总量4片Artequick 2 d疗程的给药方案治疗,观察近期治愈率、近期复发率以及平均原虫复燃天数等有效性指标,并评价其安全性。【结果】62例患者经治疗后临床症状较快缓解,平均原虫转阴时间为(60.7±23.9)h,平均退热时间为(14.1±7.8)h,其中54例完成28 d观察,近期治愈率为94.4%(51/54例),近期复发率为5.6%(3/54例)。本组病例对Artequick的耐受性良好,仅有少数病人出现恶心、呕吐;且为自限性;比较服药前与服药后第7天的血液、生化、心电图等指标,未发现Artequick片有明显的毒性。【结论】青蒿素哌喹片治疗间日疟,具有高效、速效、副反应少等优点,值得临床推广应用。
【Objective】 To observe the efficacy, safety and clinical dose of Artequick in the treatment of Plasmodium vivax. 【Method】 Sixty-two patients with Plasmodium falciparum were treated with 4 Artequick 2-day treatment regimens. The effective rate of immediate cure, recent recurrence and average number of resurgence days of protozoa were observed and evaluated for safety . 【Results】 The clinical symptoms of 62 patients were relieved quickly after treatment. The mean time to parasitemia was (60.7 ± 23.9) h and the average time of fever was (14.1 ± 7.8) h, of which 54 patients completed 28 days and were cured recently The rate was 94.4% (51/54 cases), the recent recurrence rate was 5.6% (3/54 cases). Artequick was well tolerated in this group of patients with nausea and vomiting in only a few patients and was self-limiting. No significant differences were observed in blood, biochemical, and electrocardiographic parameters before and 7 days after treatment Toxicity. 【Conclusion】 Artemisinin and piperaquine tablets have the advantages of high efficiency, quick response and few side effects in the treatment of P. vivax, which is worthy of clinical application.